Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Rocket Pharmaceuticals, Inc.    RCKT

ROCKET PHARMACEUTICALS, INC.

(RCKT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Rocket Pharmaceuticals : Announces Participation at Upcoming Conferences

share with twitter share with LinkedIn share with facebook
09/04/2020 | 08:02am EDT

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces participation at the following upcoming conferences:

  • Citi's 15th Annual BioPharma Virtual Conference
    • Gaurav Shah, M.D., President and CEO, is scheduled to participate in a fireside chat on Thursday, September 10, 2020, at 1:30 p.m. Eastern Time.
    • Jonathan D. Schwartz, M.D., Chief Medical Officer and Senior Vice President, is scheduled to participate on a panel for Benign Hematology on Thursday, September 10, 2020, at 4:15 p.m. Eastern Time.
  • Morgan Stanley’s 18th Annual Global Healthcare Virtual Conference
    • Gaurav Shah, M.D., President and CEO, is scheduled to participate in a fireside chat on Thursday, September 17, 2020, at 2:00 p.m. Eastern Time.

A live audio webcast of the presentations will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentations will be archived on the Rocket website following the conferences.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit www.rocketpharma.com.

© Business Wire 2020

share with twitter share with LinkedIn share with facebook
All news about ROCKET PHARMACEUTICALS, INC.
10/19ROCKET PHARMACEUTICALS : Presents Positive LAD-l Clinical Update and Comprehensi..
AQ
10/16ROCKET PHARMACEUTICALS : nbsp;Presents Positive†LAD-l Clinical Update and Compre..
BU
10/02ROCKET PHARMACEUTICALS : Announces Two Presentations at the European Society for..
AQ
10/01ROCKET PHARMACEUTICALS : Announces Two Presentations at the European Society for..
BU
09/25ROCKET PHARMACEUTICALS : Announces Participation at Upcoming Conferences
AQ
09/24ROCKET PHARMACEUTICALS : Announces Participation at Upcoming Conferences
BU
09/04ROCKET PHARMACEUTICALS : Announces Participation at Upcoming Conferences
BU
09/02ROCKET PHARMACEUTICALS : Announces First Patient Treated in Higher Dose Cohort i..
BU
08/27ROCKET PHARMACEUTICALS : Receives FDA Fast Track Designation for RP-L401 Gene Th..
BU
08/26ROCKET PHARMACEUTICALS : Expands Clinical Sites for its FA, Danon, LAD-I and IMO..
BU
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -105 M - -
Net cash 2020 286 M - -
P/E ratio 2020 -15,0x
Yield 2020 -
Capitalization 1 542 M 1 542 M -
EV / Sales 2020 -
EV / Sales 2021 133x
Nbr of Employees 79
Free-Float 91,0%
Chart ROCKET PHARMACEUTICALS, INC.
Duration : Period :
Rocket Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCKET PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 36,90 $
Last Close Price 27,94 $
Spread / Highest target 68,2%
Spread / Average Target 32,1%
Spread / Lowest Target 11,0%
EPS Revisions
Managers
NameTitle
Gaurav Shah President, Chief Executive Officer & Director
Roderick T. Wong Chairman
Kinnari Patel Chief Operating Officer & EVP-Development
Jonathan David Schwartz Chief Medical Officer & SVP-Clinical Development
Pedro P. Granadillo Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCKET PHARMACEUTICALS, INC.22.76%1 542
GILEAD SCIENCES, INC.-10.51%72 904
REGENERON PHARMACEUTICALS44.76%57 199
VERTEX PHARMACEUTICALS-4.84%54 210
WUXI APPTEC CO., LTD.71.31%40 863
BEIGENE, LTD.78.89%26 872